Published in Lab Business Week, June 13th, 2004
For the quarter ended March 31, 2004, the net income applicable to common stock was $2.4 million, or $0.11 income per fully diluted share, compared to a net loss applicable to common stock of $3.0 million, or $0.15 loss per fully diluted share, for the first quarter of 2003.
Total revenue increased 61% to $15.2 million in the first quarter 2004 compared to $9.5 million for the quarter ended March 31, 2003. The revenue increase was due primarily to $7.0 million in sales and royalty revenue earned from the continued growth of the Eligard...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.